Tag: drug
TB survivors seek govt clarification on continuity of TB medicines &...
India’s treatment protocols for drug-resistant TB increasingly rely on newer and repurposed medicines such as bedaquiline, delamanid, linezolid, clofazimine, and pretomanid, including newer regimens such as BPaL/BPaLM for highly drug-resistant TB
IAN Alpha Fund co-leads ₹70 Cr Series A funding round in...
The investment strengthens Peptris’ proposition as one of the leading Indian AI drug discovery platforms progressing beyond molecule generation towards clinical-ready assets
Pricing and reimbursement delays critical headwind for biopharma industry innovation, finds...
The tougher price controls and policy shifts could erode revenues, slow launches, and weaken future drug development
OneSource-Hikma partnership secures approval to commercialise generic version of Ozempic in...
Under the exclusive agreement, OneSource will manufacture and supply semaglutide from its state- of-the-art integratedBiologics and Drug-Device Combination facility
Aragen launches CHOMax™ reducing DNA to clinical supply to 10 months
Integrated cell line development, process development, analytics, GMP drug substance, plus drug product support through qualified partners
Elsevier launches LeapSpace: An AI-Assisted workspace to accelerate research and discovery
New integrated workspace will combine the broadest collection of trusted scientific content with responsible AI to help researchers move from curiosity to discovery faster
India–Ethiopia advance pharma collaboration in high-level DCGI meeting
Ethiopian Health Ministry delegation explores regulatory alignment, Indian Pharmacopeia adoption, and expanded partnership opportunities with India’s drug regulatory ecosystem
Cordis unveils positive results for two SELUTION SLR DEB trials
SELUTION DeNovo Trial – the largest randomized Drug-Eluting Balloon trial - demonstrates a SELUTION SLR™ DEB strategy is non-inferior to a Drug-Eluting Stent treatment strategy in de novo lesions
Zydus receives USFDA Orphan Drug Designation for Desidustat for the treatment...
Orphan drug designation by the USFDA for Desidustat, provides eligibility for a potential seven-year marketing exclusivity subject to the USFDA approval
NIT Rourkela scientists uncover sugar–protein link to advance bone regeneration technology
The research insights can help in developing improved biomaterials and drug delivery systems for the treatment of bone fractures, spinal injuries, and degenerative bone diseases